# The Efficacy and Safety of Gemcitabine in Combination With Docetaxel to Treat Pancreatic or Biliary Cancer

> **NCT00268840** · PHASE2 · COMPLETED · sponsor: **ARCAGY/ GINECO GROUP** · enrollment: 45 (actual)

## Conditions studied

- Pancreatic Neoplasms
- Biliary Tract Neoplasms

## Interventions

- **DRUG:** Docetaxel
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT00268840
- **Lead sponsor:** ARCAGY/ GINECO GROUP
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-08
- **Primary completion:** 2006-02
- **Final completion:** 2006-02
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2011-06-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00268840

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00268840, "The Efficacy and Safety of Gemcitabine in Combination With Docetaxel to Treat Pancreatic or Biliary Cancer". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT00268840. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*